New compounds break up cancer-causing protein STAT3 and destroy breast cancer tumors.
Ninety years after Australian scientists began their race to stop the spread of Spanish flu in Australia, University of Melbourne researchers are hoping records from the 1918 epidemic may hold the key to preventing future deadly pandemic outbreaks. This month marks the 90th anniversary of the return of Australian WWI troops from Europe, sparking Australian
Full Post: 1918 Spanish flu records could hold the key to solving future pandemics
Two new compounds created by a University of Central Florida professor show early promise for destroying breast cancer tumors.
Associate Professor James Turkson’s compounds disrupt the formation and spread of breast cancer tumors in tests on mice. The compounds, S3I-201 and S3I-M2001, break up a cancer-causing protein called STAT3, and researchers have observed no negative side effects so far.
“The compounds are very promising,” Turkson said. “They’ve worked very well in mice, and now we’re looking for partners to help us take these compounds to the next level of trials.”
Turkson’s research has been published in the academic journals Proceedings of the National Academy of Sciences and ACS Chemical Biology, and he has obtained patents for both compounds.
Turkson is passionate about his research and has a very personal reason for wanting to find a cure for cancer. During his first year of college, his 52-year-old mother was diagnosed with uterine cancer and died. He dedicated his life to finding a cure.
The two compounds developed in his lab hold promise in part because they efficiently disrupt the abnormally active STAT3 protein he said.
“We all have the STAT3 protein in our bodies, and under normal circumstances it causes no harm. But in breast cancer patients, the protein is abnormally active. It never shuts off.”
When that happens, the protein goes into overdrive and is bent on supporting the proliferation of breast cancer cells. The protein even creates a network of blood vessels to feed the cancer cells, support their growth and eventually promote the spread of the cancer into the blood, bones and organs.
“Our compounds go after STAT3, stripping away its power,” Turkson said.
Both compounds disrupt the bonding process that one STAT3 molecule goes through to connect with another in the body. If the STAT3 can’t bond to stay abnormally-active, cancer cells can’t develop. The network of blood vessels that formed to feed the cancer cells also shuts off.
Left without their source of food, the existing cancer cells die off. The body’s immune system, which until now has been tricked by the abnormally active STAT3 into thinking the tumor cells are harmless, also recognizes that something is wrong. The immune system re-activates, recognizes any remaining cancer cells as harmful and destroys them.
Turkson worked with researchers at the H. Lee Moffitt Cancer Center and Research Institute, and the Beckman Research Institute and the Comprehensive Cancer Center of the City of Hope National Medical Center.
Turkson is a native of Ghana, West Africa. He completed his studies and obtained his honors B.S. degree in Biochemistry with Chemistry at the University of Ghana. He earned a Ph.D. in Pharmacology from the University of Alberta in Canada.
He completed post-doctoral fellow training in Molecular Oncology at the H. Lee Moffitt Cancer Center and Research Institute in Tampa, where he served as an assistant professor before joining UCF’s Burnett School of Biomedical Sciences in 2005.
While Turkson continues to look for partners to further his research, he’s already working on a similar compound for pancreatic cancer.
In that case the compound would enhance the potency of another drug and use the body’s immune system to make the effect more powerful.
Molecules of sugar sitting on the surface of cancer cells are keys to the development of a new vaccine aimed at both treating and stopping the spread of certain types of cancers called carcinomas, which include prostate, breast, ovarian and lung, among others. Armed with a new two-year grant for $600,000 from the Gateway for
Full Post: Novel low-cost immunotherapy for cancer cells
A new study reveals that the metadherin gene (MTDH) plays a role in both cancer metastasis and resistance to chemotherapy. The research, published by Cell Press in the January 6th issue of the journal Cancer Cell , identifies MTDH as a promising therapeutic target for high risk breast cancers. “Most breast cancer patients resist currently
Full Post: Metadherin gene plays dual role in breast cancers with poor prognosis
Canadian researchers have identified a new protein in the progression of breast cancer. According to a recent study from the Université de Montréal and the University of Alberta, published in the Journal of Biological Chemistry, the protein ARF1 plays a critical role in cancer cell growth and the spread of tumours. Targeting this protein with
Full Post: Discovery of new protein that triggers breast cancer
In an important finding published online in Developmental Cell, researchers at Albert Einstein College of Medicine of Yeshiva University, along with collaborators at Massachusetts Institute of Technology, have identified a protein likely responsible for causing breast cancer to spread. Metastatic cancer occurs when cancer cells from the original tumor travel to distant sites via the
Full Post: Discovery of protein that may cause breast cancer to spread
If scientists knew exactly what a breast cancer cell needs to spread, then they could stop the most deadly part of the disease: metastasis. New research from the University of North Carolina at Chapel Hill School of Medicine takes a step in that direction. Carol Otey, Ph.D. and UNC colleagues reduced the ability of breast
Full Post: Palladin may play important role in metastasis of breast cancer cells